The drug behind the $4.25 million headline is Lenmeldy (atidarsagene autotemcel), a one-time gene therapy for children with certain forms of metachromatic leukodystrophy (MLD). The figure is its reported U.S. list price for a single treatment—not necessarily what an insurer pays after negotiations or what a family owes. A 2026 U.S. House committee document identifies $4.25 million as the highest list price for a single-dose gene therapy in 2025, so the ranking is date- and measure-specific, not a timeless claim about every drug worldwide.
What is Lenmeldy, and who can receive it?
The U.S. Food and Drug Administration (FDA) approved Lenmeldy on March 18, 2024. Its label covers children with presymptomatic late-infantile MLD, presymptomatic early-juvenile MLD, or early-symptomatic early-juvenile MLD. It is not approved for every person with MLD or for all disease stages. The FDA approval announcement describes the approved groups and treatment evidence; the FDA Lenmeldy page links to current product information.
MLD is a rare inherited disease affecting the brain and nervous system. According to the FDA, deficiency of the arylsulfatase A (ARSA) enzyme allows sulfatides to build up in cells, damaging the central and peripheral nervous systems. The disease can cause progressive loss of motor and cognitive abilities and early death. The FDA estimates that MLD affects about one in every 40,000 people in the United States.
Why does one treatment cost $4.25 million?
The $4.25 million figure is a U.S. list price—also described as wholesale acquisition cost—for one treatment. A 2026 document from the U.S. House Committee on Energy and Commerce identifies it as the highest list price for a single-dose gene therapy in 2025. Nature Biotechnology also reported the $4.25 million launch price in April 2024 (Nature Biotechnology).
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Repair Windows errors before they cause bigger problemsFix Now →#1 Best Overall
A list price is not the same as a negotiated payment. The figure alone does not tell a reader what a health plan ultimately pays, whether coverage terms or other arrangements change the amount, or what a particular family owes out of pocket. Those amounts depend on the insurer, coverage decision and patient circumstances; the sources cited here do not establish a universal net price or family bill.
The “most expensive” label also needs its comparison defined. The House document supports a claim about the highest U.S. list price for a single-dose gene therapy in 2025. It does not establish a permanent worldwide ranking across all medicines and pricing measures. A one-time treatment price should not be compared with the annual cost of a recurring medicine as if the time horizons were identical.
How does the therapy work?
Lenmeldy is made using the patient’s own blood-forming hematopoietic stem cells. Clinicians collect the cells, modify them to include functional copies of the ARSA gene, then infuse them back into the patient. After engrafting in bone marrow, the modified cells produce cells that supply ARSA enzyme. That enzyme helps break down sulfatides and may stop disease progression.
This is a specialist treatment pathway, not a medicine taken at home. The FDA’s approval summary explains the cell-collection and gene-modification approach.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
What benefits did the FDA report?
The FDA said Lenmeldy significantly reduced the risk of severe motor impairment or death compared with untreated children in natural-history data. In the presymptomatic late-infantile group, all treated children were alive at age six, compared with 58% of children in the natural-history comparison group. At age five, 71% of treated children could walk without assistance, and 85% had normal language and performance IQ scores. Children treated in the presymptomatic or early-symptomatic early-juvenile groups showed slowed motor and/or cognitive disease progression.
These results are encouraging, but the evidence base is small: Nature Biotechnology summarized the approval evidence as involving 37 pediatric patients. The comparisons were with natural history, not a randomized head-to-head trial. The reported outcomes describe study groups and do not guarantee what will happen for an individual child. See the FDA’s clinical summary and Nature Biotechnology’s account of the approval evidence.
Rank #4
What are the risks and follow-up requirements?
The FDA lists fever, low white blood cell count, mouth sores, respiratory infections, rash, line infections, viral and gastrointestinal infections, and an enlarged liver among common side effects. It also describes risks including delayed platelet engraftment, blood clots and encephalitis. The FDA noted a potential risk of blood cancer, although no cases had been reported among treated patients at the time of approval.
Because of that potential risk, the FDA calls for lifelong monitoring for hematologic malignancies, including annual complete blood counts and integration-site analysis as warranted for at least 15 years. Families and clinicians should review the current product information and the child’s individual treatment plan with the specialist team. The FDA’s safety summary describes the listed risks and monitoring.
The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Quick Recap
What the price headline does—and does not—tell you
- What it tells you: Lenmeldy had a reported U.S. list price of $4.25 million for a single treatment, and a 2026 House committee document identifies that as the highest list price for a single-dose gene therapy in 2025.
- What it does not tell you: The amount a payer ultimately pays, a family’s out-of-pocket cost, or a lasting worldwide ranking across all medicines.
- What the treatment is: A one-time, individualized gene therapy for children in specific MLD groups—not a general treatment for every person with the disease.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
